{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T03:41:46Z","timestamp":1773286906119,"version":"3.50.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,10]],"date-time":"2015-04-10T00:00:00Z","timestamp":1428624000000},"content-version":"vor","delay-in-days":1195,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.bbmt.2011.10.022","type":"journal-article","created":{"date-parts":[[2012,1,9]],"date-time":"2012-01-09T10:44:55Z","timestamp":1326105895000},"page":"S125-S131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"S","title":["Emerging Therapies in Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","volume":"18","author":[{"given":"Pavan","family":"Reddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Koreth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2011.10.022_bib1","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","article-title":"Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria","volume":"117","author":"Flowers","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.022_bib2","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1182\/blood.V98.12.3192","article-title":"The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation","volume":"98","author":"Ho","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.022_bib3","doi-asserted-by":"crossref","first-page":"6963","DOI":"10.1182\/blood-2011-01-332007","article-title":"Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies","volume":"117","author":"Soiffer","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.022_bib4","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bmt.1705315","article-title":"HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation","volume":"37","author":"Ho","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.10.022_bib5","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2011.10.022_bib6","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev.immunol.16.1.225","article-title":"NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses","volume":"16","author":"Ghosh","year":"1998","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bbmt.2011.10.022_bib7","doi-asserted-by":"crossref","first-page":"788","DOI":"10.4049\/jimmunol.160.2.788","article-title":"Role of proteasomes in T cell activation and proliferation","volume":"160","author":"Wang","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2011.10.022_bib8","first-page":"1419","article-title":"Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma","volume":"7","author":"Sunwoo","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2011.10.022_bib9","doi-asserted-by":"crossref","first-page":"5994","DOI":"10.4049\/jimmunol.167.10.5994","article-title":"Inhibition of NF-kappaB-dependent T cell activation abrogates acute allograft rejection","volume":"167","author":"Finn","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2011.10.022_bib10","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1182\/blood-2005-08-3494","article-title":"Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation","volume":"108","author":"Nencioni","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.022_bib11","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2010-05-284737","article-title":"Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis","volume":"117","author":"Hirai","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.022_bib12","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1182\/blood-2005-05-2118","article-title":"Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines","volume":"107","author":"Blanco","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.022_bib13","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1073\/pnas.0401563101","article-title":"Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib","volume":"101","author":"Sun","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bbmt.2011.10.022_bib14","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1182\/blood-2004-11-4526","article-title":"Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity","volume":"106","author":"Sun","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.022_bib15","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood-2005-05-1820","article-title":"NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145","volume":"107","author":"Vodanovic-Jankovic","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.022_bib16","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2002-09-2975","article-title":"The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP","volume":"102","author":"Sayers","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.022_bib17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4049\/jimmunol.180.1.163","article-title":"Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition","volume":"180","author":"Hallett","year":"2008","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.bbmt.2011.10.022_bib18","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1182\/blood-2008-05-158253","article-title":"Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in\u00a0vitro expanded natural killer cells, which are functionally enhanced by bortezomib","volume":"113","author":"Yong","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.022_bib19","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1158\/0008-5472.CAN-06-4274","article-title":"The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells","volume":"67","author":"Liu","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2011.10.022_bib20","doi-asserted-by":"crossref","first-page":"4757","DOI":"10.4049\/jimmunol.176.8.4757","article-title":"Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade)","volume":"176","author":"Schumacher","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.bbmt.2011.10.022_bib21","doi-asserted-by":"crossref","first-page":"7317","DOI":"10.1158\/0008-5472.CAN-06-0680","article-title":"Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity","volume":"66","author":"Lundqvist","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.bbmt.2011.10.022_bib22","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0092-8674(94)90462-6","article-title":"Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules","volume":"78","author":"Rock","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.bbmt.2011.10.022_bib23","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2006-10-054221","article-title":"Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications","volume":"109","author":"Spisek","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.022_bib24","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1182\/blood-2009-07-231092","article-title":"Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors","volume":"114","author":"Koreth","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.022_bib25","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.beha.2010.09.016","article-title":"Have we made progress in the management of chronic graft-vs-host disease?","volume":"23","author":"Lee","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.bbmt.2011.10.022_bib26","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.exphem.2006.02.020","article-title":"Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status","volume":"34","author":"Kroger","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2011.10.022_bib27","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2008-03-143461","article-title":"Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation","volume":"112","author":"Sun","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.022_bib28","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1182\/blood-2008-11-190421","article-title":"Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells","volume":"113","author":"Lundqvist","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.022_bib29","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2003-03-0687","article-title":"Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2\u2032-deoxycytidine (decitabine) in hematopoietic malignancies","volume":"103","author":"Issa","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.022_bib30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2011.10.022_bib31","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/cncr.11184","article-title":"Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias","volume":"97","author":"de Lima","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2011.10.022_bib32","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0140-6736(84)90900-0","article-title":"Modulation of HLA-DR antigens expression in human myeloid leukaemia cells by cytarabine and 5-aza-2\u2032-deoxycytidine","volume":"2","author":"Pinto","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2011.10.022_bib33","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/blood.V64.4.922.922","article-title":"5-Aza-2\u2032-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias","volume":"64","author":"Pinto","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.022_bib34","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1182\/blood-2008-05-158956","article-title":"Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy","volume":"113","author":"Hambach","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.022_bib35","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/cncr.24198","article-title":"Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia","volume":"115","author":"Jabbour","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2011.10.022_bib36","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1740774507076934","article-title":"Simultaneously optimizing dose and schedule of a new cytotoxic agent","volume":"4","author":"Braun","year":"2007","journal-title":"Clin Trials"},{"key":"10.1016\/j.bbmt.2011.10.022_bib37","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.bbmt.2010.09.022","article-title":"Clofarabine +\/\u2212 fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS","volume":"17","author":"Andersson","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2011.10.022_bib38","article-title":"Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial","author":"Platzbecker","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2011.10.022_bib39","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2009-03-210393","article-title":"Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting","volume":"115","author":"Sanchez-Abarca","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.022_bib40","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2009-12-257253","article-title":"In\u00a0vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia","volume":"116","author":"Choi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.022_bib41","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1126\/science.1063127","article-title":"Translating the histone code","volume":"293","author":"Jenuwein","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2011.10.022_bib42","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1126\/science.159.3812.314","article-title":"Histone acetylation in insect chromosomes","volume":"159","author":"Allfrey","year":"1968","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2011.10.022_bib43","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nrm2346","article-title":"The Rpd3\/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men","volume":"9","author":"Yang","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.bbmt.2011.10.022_bib44","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"Mann","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.bbmt.2011.10.022_bib45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.022_bib46","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1073\/pnas.052702999","article-title":"The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines","volume":"99","author":"Leoni","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2011.10.022_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2119\/2006-00005.Dinarello","article-title":"The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in\u00a0vitro and systemic inflammation in\u00a0vivo","volume":"11","author":"Leoni","year":"2005","journal-title":"Mol Med"},{"key":"10.1016\/j.bbmt.2011.10.022_bib48","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1073\/pnas.0400380101","article-title":"Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect","volume":"101","author":"Reddy","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bbmt.2011.10.022_bib49","first-page":"2562","article-title":"Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice","volume":"118","author":"Reddy","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bbmt.2011.10.022_bib50","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1172\/JCI16153","article-title":"Histone deacetylase inhibitors modulate renal disease in the MRL-lpr\/lpr mouse","volume":"111","author":"Mishra","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bbmt.2011.10.022_bib51","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood-2002-07-2073","article-title":"Histone deacetylase inhibitors: a new class of immunosuppressors targeting a novel signal pathway essential for CD154 expression","volume":"101","author":"Skov","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2011.10.022_bib52","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.4049\/jimmunol.176.8.5015","article-title":"Histone hyperacetylation is associated with amelioration of experimental colitis in mice","volume":"176","author":"Glauben","year":"2006","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.bbmt.2011.10.022_bib53","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/gut.2007.134650","article-title":"Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice","volume":"57","author":"Glauben","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.bbmt.2011.10.022_bib54","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/nm1652","article-title":"Deacetylase inhibition promotes the generation and function of regulatory T cells","volume":"13","author":"Tao","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.bbmt.2011.10.022_bib55","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.exphem.2006.02.014","article-title":"Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1","volume":"34","author":"Leng","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2011.10.022_bib56","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nri2000","article-title":"Graft-versus-host disease","volume":"7","author":"Shlomchik","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bbmt.2011.10.022_bib57","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1146\/annurev.immunol.18.1.767","article-title":"Immunobiology of dendritic cells","volume":"18","author":"Banchereau","year":"2000","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.bbmt.2011.10.022_bib58","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.4049\/jimmunol.0804388","article-title":"Cutting edge: negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3","volume":"182","author":"Sun","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2011.10.022_bib59","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1083-8791(03)70009-3","article-title":"Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy","volume":"9","author":"Levine","year":"2003","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879111004253?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879111004253?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:40:08Z","timestamp":1761057608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879111004253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S1083879111004253"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2011.10.022","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging Therapies in Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2011.10.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}